Step-by-step Optimisation of the Radiosynthesis of the Brain HDAC6 Radioligand [F]FSW-100 for Clinical Applications

Overview

Journal EJNMMI Radiopharm Chem

Date 2024 Jun 3

PMID 38831171

Authors

Tetsuro Tago

Jun Toyohara

Affiliations

Soon will be listed here.

Abstract

Background: Histone deacetylase 6 (HDAC6) is an emerging target for the treatment and diagnosis of proteinopathies. [F]FSW-100 was recently developed as a promising brain-penetrating radioligand for HDAC6 PET imaging and the process validation of [F]FSW-100 radiosynthesis for clinical use is complete, but no detailed synthetic strategy nor process optimisation has been reported. Here, we describe the optimisation of several processes in [F]FSW-100 radiosynthesis, including the F-fluorination reaction, semipurification of the F-intermediate, and purification of the product by high-performance liquid chromatography (HPLC), to achieve a radiochemical yield (RCY) adequate for clinical applications of the radioligand. Our findings will aid optimisation of radiosynthesis processes in general.

Results: In the F-fluorination reaction, the amount of copper reagent was reduced without reducing the nonisolated RCY of the intermediate (50%), thus reducing the risk of copper contamination in the product injection solution. Optimising the solid-phase extraction (SPE) conditions for semipurification of the intermediate improved its recovery efficiency. The addition of anti-radiolysis reagents to the mobile phase for the HPLC purification of [F]FSW-100 increased its activity yield in radiosynthesis using a high [F]fluoride radioactivity of approximately 50 GBq. The SPE-based formulation method and additives for the injection solution were optimised, and the resulting [F]FSW-100 injection solution was stable for over 2 h with a radiochemical purity of greater than 95%.

Conclusions: Of all the reconsidered processes, we found that optimisation of the SPE-based semipurification of the intermediate and of the mobile phase for HPLC purification in particular improved the RCY of [F]FSW-100, doubling it compared to that of the original protocol. The radioactivity of [F]FSW-100 synthesized using the optimized protocol was sufficient for multiple doses for a clinical study.

References

Onishi T, Maeda R, Terada M, Sato S, Fujii T, Ito M . A novel orally active HDAC6 inhibitor T-518 shows a therapeutic potential for Alzheimer's disease and tauopathy in mice. Sci Rep. 2021; 11(1):15423. PMC: 8322070. DOI: 10.1038/s41598-021-94923-w. View

Scott P, Hockley B, Kung H, Manchanda R, Zhang W, Kilbourn M . Studies into radiolytic decomposition of fluorine-18 labeled radiopharmaceuticals for positron emission tomography. Appl Radiat Isot. 2008; 67(1):88-94. PMC: 5938091. DOI: 10.1016/j.apradiso.2008.08.015. View

Ding H, Dolan P, Johnson G . Histone deacetylase 6 interacts with the microtubule-associated protein tau. J Neurochem. 2008; 106(5):2119-30. PMC: 2574575. DOI: 10.1111/j.1471-4159.2008.05564.x. View

Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J . Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013; 79(6):1094-108. PMC: 3809845. DOI: 10.1016/j.neuron.2013.07.037. View

Mossine A, Tanzey S, Brooks A, Makaravage K, Ichiishi N, Miller J . One-pot synthesis of high molar activity 6-[F]fluoro-l-DOPA by Cu-mediated fluorination of a BPin precursor. Org Biomol Chem. 2019; 17(38):8701-8705. PMC: 6812483. DOI: 10.1039/c9ob01758e. View

Tago T, Toyohara J, Ishii K . Preclinical Evaluation of an F-Labeled SW-100 Derivative for PET Imaging of Histone Deacetylase 6 in the Brain. ACS Chem Neurosci. 2021; 12(4):746-755. DOI: 10.1021/acschemneuro.0c00774. View

Haider A, Zhao C, Wang L, Xiao Z, Rong J, Xia X . Assessment of cholesterol homeostasis in the living human brain. Sci Transl Med. 2022; 14(665):eadc9967. PMC: 9581941. DOI: 10.1126/scitranslmed.adc9967. View

Mossine A, Brooks A, Ichiishi N, Makaravage K, Sanford M, Scott P . Development of Customized [F]Fluoride Elution Techniques for the Enhancement of Copper-Mediated Late-Stage Radiofluorination. Sci Rep. 2017; 7(1):233. PMC: 5427906. DOI: 10.1038/s41598-017-00110-1. View

Guo W, Naujock M, Fumagalli L, Vandoorne T, Baatsen P, Boon R . HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients. Nat Commun. 2017; 8(1):861. PMC: 5636840. DOI: 10.1038/s41467-017-00911-y. View

10.

Bowden G, Chailanggar N, Pichler B, Maurer A . Scalable F processing conditions for copper-mediated radiofluorination chemistry facilitate DoE optimization studies and afford an improved synthesis of [F]olaparib. Org Biomol Chem. 2021; 19(32):6995-7000. DOI: 10.1039/d1ob00903f. View

11.

Hoffmann C, Kolks N, Smets D, Haseloer A, Groner B, Urusova E . Next Generation Copper Mediators for the Efficient Production of F-Labeled Aromatics. Chemistry. 2022; 29(2):e202202965. PMC: 10100267. DOI: 10.1002/chem.202202965. View

12.

Tredwell M, Preshlock S, Taylor N, Gruber S, Huiban M, Passchier J . A general copper-mediated nucleophilic 18F fluorination of arenes. Angew Chem Int Ed Engl. 2014; 53(30):7751-5. DOI: 10.1002/anie.201404436. View

13.

Kozikowski A, Shen S, Pardo M, Tavares M, Szarics D, Benoy V . Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome. ACS Chem Neurosci. 2018; 10(3):1679-1695. PMC: 6512341. DOI: 10.1021/acschemneuro.8b00600. View

14.

Li Y, Shin D, Kwon S . Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes. FEBS J. 2012; 280(3):775-93. DOI: 10.1111/febs.12079. View

15.

Wright J, Kaur T, Preshlock S, Tanzey S, Winton W, Sharninghausen L . Copper-Mediated Late-stage Radiofluorination: Five Years of Impact on Pre-clinical and Clinical PET Imaging. Clin Transl Imaging. 2021; 8(3):167-206. PMC: 7968072. DOI: 10.1007/s40336-020-00368-y. View

16.

Bai P, Mondal P, Bagdasarian F, Rani N, Liu Y, Gomm A . Development of a potential PET probe for HDAC6 imaging in Alzheimer's disease. Acta Pharm Sin B. 2022; 12(10):3891-3904. PMC: 9532562. DOI: 10.1016/j.apsb.2022.05.017. View

17.

Perez-Roses R, Risco E, Vila R, Penalver P, Canigueral S . Antioxidant activity of Tween-20 and Tween-80 evaluated through different in-vitro tests. J Pharm Pharmacol. 2015; 67(5):666-72. DOI: 10.1111/jphp.12369. View

18.

Mossine A, Tanzey S, Brooks A, Makaravage K, Ichiishi N, Miller J . Synthesis of high-molar-activity [F]6-fluoro-L-DOPA suitable for human use via Cu-mediated fluorination of a BPin precursor. Nat Protoc. 2020; 15(5):1742-1759. PMC: 7333241. DOI: 10.1038/s41596-020-0305-9. View

19.

Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, Koole M . Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med. 2009; 50(8):1251-9. DOI: 10.2967/jnumed.109.063305. View

20.

Kawaguchi Y, Kovacs J, McLaurin A, Vance J, Ito A, Yao T . The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell. 2003; 115(6):727-38. DOI: 10.1016/s0092-8674(03)00939-5. View